Latest Intelligence on Biotech

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Roche: Piramed acquisition strengthens its oncology and I&I portfolio

Roche has agreed to acquire Piramed for $160m plus a milestone payment of $15m, due upon the start of Phase II clinical trials for the company's oncology program. Piramed's oncology and immunology and inflammation programs will add to Roche's already strong portfolio in these therapy areas and the move is in line with Roche's strategy of pursuing these two fastest growing therapeutic segments.

Published By Datamonitor
15 Apr 2008
CommentWire
CommentWire

Eli Lilly: completes SGX acquisition

Eli Lilly has completed its purchase of US biotechnology company SGX Pharmaceuticals for $64m. The acquisition is expected to compliment Lilly's pursuit of innovative R&D programs, and represents a further investment by a leading pharmaceutical player in the promising US biotechnology industry.

Published By Datamonitor
21 Aug 2008
CommentWire
CommentWire

UCB: Cimzia's indication expansion hindered by FDA

Although the FDA's complete response letter for Cimzia in rheumatoid arthritis will delay its US approval, Datamonitor believes UCB has the experience to handle the setback and the drug may still reach the market by the second half of 2009. Ultimately however, the delay will not be a major impediment as extensive uptake is not expected at launch due to poor differentiation in a mature drug class.

Published By Datamonitor
07 Jan 2009
Expert View
Expert View

Genentech/Merck Serono: is this the end of the line for Raptiva?

Raptiva's safety profile continues to face US and EU regulatory agency scrutiny, which Datamonitor believes will have significant ramifications for the drug's use in psoriasis and any future employment in transplantation. With fresh concern over the safety of Genentech's drug, alternative therapies are likely to impact upon Raptiva's commercial potential.

Published By Datamonitor
23 Feb 2009
CommentWire
CommentWire

Genentech/Roche/Chugai: Herceptin shows activity in gastric cancer

Already a widely used therapy in HER-2-positive breast cancer patients, Herceptin now has the potential to establish itself in the equivalent gastric cancer subset following positive survival results in a pivotal trial. However, with other top-selling targeted therapy drugs also in late-stage development for the same indication, competition is on the horizon.

Published By Datamonitor
18 Mar 2009
CommentWire
CommentWire

Genentech/Roche: Avastin adds fifth indication to label

Following positive results from two Phase II trials, Genentech/Roche's Avastin has obtained accelerated FDA approval for glioblastoma patients who have progressed after previous treatment. While the commercial potential in this indication is small, it creates an opportunity for Avastin to become an established treatment in this type of brain cancer.

Published By Datamonitor
06 May 2009
Expert View
Expert View

World Vaccine Congress Asia: vast regional diversity requires flexibility and targeted portfolios

Spanning one third of the globe's circumference and home to more than half of the world's population, the Asia Pacific region is incredibly diverse. This year's World Vaccine Congress Asia highlighted the enormous variation in the vaccine landscape in the region, owing to a myriad of political, cultural, economic and geographic differences.

Published By Datamonitor
24 Jun 2009
Expert View
Expert View

World Vaccine Congress Asia: new partnerships open doors to regional markets

At the World Vaccine Congress Asia, it became apparent that new local facilities and partnerships are essential to expand supply, thus providing openings into the emerging vaccine markets of the region. GlaxoSmithKline and Sanofi Pasteur are leading in the space, overcoming low levels of disease awareness and financial shortages to secure a strong foothold in Asia.

Published By Datamonitor
24 Jun 2009
CommentWire
CommentWire

Jazz Pharmaceuticals/UCB: fibromyalgia beckons for narcolepsy drug

New positive top-line results from a second Phase III clinical trial of sodium oxybate in fibromyalgia show that the drug is on track for FDA approval. As such, the treatment is set to enter the market as the fourth drug to be approved for fibromyalgia in the US. Despite impressive efficacy data, however, prescriptions are likely to be limited by accessibility, price and convenience.

Published By Datamonitor
26 Jun 2009
CommentWire
CommentWire

Biogen Idec: shifting its multiple sclerosis pipeline

Biogen's MS pipeline has been in the spotlight this week due to negative Phase II data for CDP323 and the company's announcement of an agreement to develop and commercialize Fampridine SR outside the US. While the CDP323 results have led to the drug being shelved, Biogen's continuing activity in broadening its strong MS pipeline shows its resolve in maintaining its leading position in this market.

Published By Datamonitor
02 Jul 2009

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | » »|

No help is available.